

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b> 10/084,706	<b>Applicant(s)</b> RASMUSSEN ET AL.
	<b>Examiner</b> Jegatheesan Seharaseyon, Ph.D	<b>Art Unit</b> 1647

**All Participants:**(1) Jegatheesan Seharaseyon, Ph.D.

(3) \_\_\_\_\_

(2) Margaret Powers.

(4) \_\_\_\_\_

**Date of Interview:** 20 December 2005**Time:** 1:45 P.M.**Type of Interview:**

- Telephonic  
 Video Conference  
 Personal (Copy given to:  Applicant     Applicant's representative)

Exhibit Shown or Demonstrated:  Yes     No

If Yes, provide a brief description:

**Part I.****Rejection(s) discussed:***USC 112, first paragraph (written description)***Claims discussed:***Claim 88***Prior art documents discussed:***None***Part II.****SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:***See Continuation Sheet***Part III.**

- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

The Office discussed changes to claim 88 to comply with the current written description requirements to adequately describe the genus claimed. Although, Applicants disagreed and believed that the current claims fully meet the written description requirement, in an effort to expedite prosecution, Applicants agreed to modify the claim language to specify no more than 8 amino acid changes in SEQ ID NO:2. Applicants identified support for such changes in page 17 of the specification. Applicants also stated that they specifically reserve the right to pursue and/or renew subject matter cancelled or eliminated from any claim without prejudice, including in a continuation or divisional application.